
A longevity-industry analysis puts everyday function in focus, offering better questions about product claims, travel goals and dietary fibre.

On November 4, 2026, NutraIngredients published an analysis of longevity-product messaging through the lens of Holland & Barrett. Its global product formulation lead Alex Glover argued that consumers ultimately judge products by the outcomes they experience. If you value the freedom to travel and remain active, that distinction deserves your attention.
The report covered Glover’s remarks at the Remedy Nutrafood CDMO Conference in Gdańsk. His central observation was straightforward: a compelling brand story may attract interest initially. The eventual judgment rests on what the person taking the product experiences.
For an active adult, this suggests a useful starting point for any longevity claim. Before considering the cellular explanation, ask what the proposed benefit would mean in your actual day.
According to NutraIngredients, Glover said Holland & Barrett’s consumer panels with people aged 50 and over focused on ordinary activities and independence. Abstract language about healthspan was not the center of those conversations.
He illustrated the point with a woman in her 50s who wanted to play with her grandchildren. She also wanted to rise from a chair without pain and travel without worrying about her health. Those were her priorities as Glover recounted them, rather than a universal description of everyone in her age group.
The distinction matters because a biological explanation and an everyday outcome answer different questions. The explanation describes the scientific rationale being offered. The outcome describes what someone hopes to do or experience.
Glover argued that most consumers are not focused on NAD+ levels or sirtuins or telomere length. Instead, he said they judge products by how they feel while taking them. His account suggests that naming a mechanism does not necessarily communicate a meaningful benefit.
Consider the difference between a claim about cellular health and a claim about mobility. The first needs translation before it becomes useful to someone planning an active holiday. The second gives that person a recognizable outcome to examine, although the evidence behind the claim still matters.
Glover said Holland & Barrett asked 1,000 consumers what “cellular health” meant to them. He described a wide range of responses that he interpreted as evidence that the term was unclear.
For readers, the useful response is not to memorize more terminology. It is to ask the person making the claim to explain the promised outcome in ordinary language. A clear explanation should make the proposition easier to assess without requiring you to become a specialist.
Glover also said the retailer tends to develop products around benefits that interest consumers rather than beginning with a particular ingredient or mechanism. That is a product-development perspective. For the reader, the corresponding question is whether the proposed benefit addresses something worth caring about.
This fits WealthAtPlay’s emphasis on staying strong and capable for longer. It also puts biological measurements and health tracking in a practical frame: what question is the measurement intended to answer?
Glover identified dietary fibre as an overlooked opportunity in longevity. As reported by NutraIngredients, he pointed to evidence relating to gut function and heart-disease risk as well as longevity.
The editorial lesson is useful. An everyday nutrition topic deserves attention even when its language is less elaborate than a cellular claim. Familiarity should not be a reason to overlook it, just as scientific vocabulary should not be a reason to favor something else.
Mayo Clinic Press adds an important qualification for this audience: fibre needs may be lower after age 50 or for people with gastrointestinal issues. Its guidance makes room for age and digestive circumstances rather than treating every adult as having the same requirements.
That makes fibre a reasonable subject for an ordinary nutrition conversation. Where personal health or digestive concerns affect that conversation, a qualified clinician or dietitian can help interpret what is appropriate.
The NutraIngredients article reports Glover’s industry perspective rather than an independent clinical study or a market-wide test of consumer behavior. His account of the consumer research does not include survey methods or a complete breakdown of results. It therefore does not establish that function-focused products sell better across the market, nor does it show that the biological measures he mentioned are scientifically irrelevant.
The report also provides no product-level fibre trial or intervention dose that would support a claim that a particular supplement prevents disease or extends lifespan. It does not test travel recovery or sustained sporting energy. A person’s reported experience and a demonstrated health benefit remain distinct forms of evidence.
The practical consequence of this analysis is a better way to assess promises before they become part of your routine. Travel and sport make that assessment especially tangible because the desired outcome is usually easier to describe than a broad ambition to improve longevity.
For travel recovery, the question might be whether a product has evidence for the specific difficulty you want to address. A general cellular-health story does not answer that question on its own. The useful discussion begins with the outcome rather than the ingredient’s reputation.
For hiking or skiing, sustained energy is a clearer subject than an undefined promise of vitality. It gives you something concrete to ask about: what does the seller mean by energy, and what evidence supports that meaning? The aim is clarity before commitment.
The same approach applies to independence at home. Getting comfortably out of a chair is a different objective from changing a laboratory measurement. Each deserves an explanation of its own rather than being treated as interchangeable.
This is also why physical function belongs in longevity discussions. The question is not simply whether a claim sounds advanced. It is whether the evidence addresses the capability that matters to you.
Glover identified four questions consumers ask when considering a product. Together, they offer a manageable way to examine a claim without turning daily life into a monitoring project.
The simplest practical action is to choose one personally meaningful outcome before assessing a product. That could be the travel concern already on your mind or a question about comfort during ordinary movement. There is no need to construct a complete longevity dashboard to make that first distinction.
Then keep the conversation on that outcome. If a claim begins with cellular terminology, ask how the supporting evidence connects to your stated goal. If it begins with a recognizable benefit, ask what evidence supports that benefit in the product being considered.
For fibre, the corresponding action is equally modest: treat it as a relevant nutrition topic rather than automatically converting the discussion into a supplement purchase. Personal requirements belong in an individualized conversation when age or digestive health makes the decision less straightforward.
For your next longevity decision, start with one capability you want to preserve and judge the claim by evidence for that outcome rather than the sophistication of its cellular language.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.



Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog